TERAPIYa LIRAGLUTIDOM ZNAChITEL'NO ULUChShAET KONTROL' GLIKEMII I OKAZYVAET POLOZhITEL'NOE VLIYaNIE NA SERDEChNO-SOSUDISTUYu SISTEMU PATsIENTOV S SAKhARNYM DIABETOM 2 TIPA

The article presents data on the effectiveness of therapy with long-acting human glucagon-like peptide-1 analogue liraglutide (Victoza) in the treatment of type 2 diabetes mellitus (DM2) in real clinical practice depending on the initial level of glycated hemoglobin (HbA1c), as well as results of assessment of the impact of treatment on clinical manifestations of coronary artery disease (CAD) and arterial hypertension. Were analyzed 44 patients with type 2 diabetes mellitus, which were divided into 3 groups depending on the duration of diabetes and baseline HbA1c: Group 1 received liraglutide in combination with metformin; Group 2 received liraglutide in addition to previous therapy with metformin and/or sulfonylureas (with the possibility of SU dose adjustment); Group 3 after compensation of carbohydrate metabolism using insulin analogues, with a stable normal values of blood glucose, have received liraglutide followed by complete abolition of insulin therapy. At 3 months, significant reduction in HbA1c and body mass index was found in all groups. In DM2 patients with with concomitant cardiovascular diseases, therapy with liraglutide provide significant and steady improvement in glycemic control, as well as improvement of blood pressure profile and reduction of clinical manifestations of coronary artery disease.

liraglutide, type 2 diabetes mellitus, glycemic control, coronary artery disease, arterial hypertension, hypoglycemia